Venture Builders, when VCs become Founders
|Date:||April 25, 2023|
|Time:||14:30 – 15:15|
We see more and more often that investors get educated about a technology and decide to build a biotech company from scratch. Why are investors ready to take the risks associated with early-stage companies? How much stamina is needed to get to the next level? How is venture building seen by follow-on investors? The panel tries to answer these questions.
Dani Bach, Partner, +ND Capital
Karen Wagner, Partner, Ysios Capital
Daniela Couto, Partner, BioGeneration Ventures
Alexander Mayweg, Managing Director, Versant Ventures